5.2 Initial ED & Prehospital Pharmacotherapy

Initial ED & Prehospital Pharmacotherapy

The initial pharmacological management of Acute Coronary Syndrome (ACS) focuses on alleviating ischemia, preventing further thrombus formation, and managing pain. The historical mnemonic "MONA" (Morphine, Oxygen, Nitroglycerin, Aspirin) is still widely taught, but current AHA guidelines have significantly refined the indications and sequencing of these therapies. Understanding the precise appropriate use of each agent is crucial for optimal patient care.

Oxygen Therapy

Historically, supplemental oxygen was routinely administered to all patients with suspected ACS. However, recent evidence suggests that hyperoxia can cause coronary vasoconstriction and increase the production of reactive oxygen species, potentially worsening myocardial injury.

Current Guidelines

• Indication: Administer supplemental oxygen ONLY if the patient is hypoxemic (SpO2 < 90%), experiencing significant respiratory distress, or showing signs of heart failure.
• Goal: Titrate oxygen to maintain an SpO2 of 90% or higher. Do not over-oxygenate.
• Method: Typically initiated via nasal cannula at 2-4 L/min, adjusting as needed based on pulse oximetry.

Aspirin

Aspirin is the cornerstone of early ACS pharmacotherapy. It is an irreversible cyclooxygenase (COX) inhibitor that rapidly blocks the synthesis of thromboxane A2, thereby preventing further platelet aggregation and expansion of the coronary thrombus.

Administration

• Dose: 162 mg to 325 mg.
• Formulation: Non-enteric coated, chewable aspirin is preferred because chewing facilitates rapid buccal absorption, achieving therapeutic antiplatelet effects within minutes.
• Timing: Should be given immediately upon suspicion of ACS, ideally by EMS in the prehospital setting or immediately upon ED arrival.
• Contraindications: True severe aspirin allergy (anaphylaxis) or active, severe gastrointestinal bleeding. Note that a history of mild GI intolerance is generally not a contraindication in the setting of acute ACS due to the overwhelming mortality benefit.

Nitroglycerin

Nitroglycerin (NTG) is a potent vasodilator. Its primary mechanism of action in ACS is venodilation, which decreases venous return (preload) to the heart, thereby reducing ventricular wall stress and myocardial oxygen demand. It also provides some direct coronary vasodilation, improving collateral blood flow to ischemic areas.

Administration and Dosing

• Route: Sublingual (SL) tablet or translingual spray.
• Dose: 0.4 mg every 5 minutes for ongoing chest pain, for a maximum of 3 doses.
• Assessment: Blood pressure and pain level must be reassessed before each subsequent dose.

Contraindications and Cautions

The use of NTG requires careful consideration of the patient's hemodynamic status. It is strictly contraindicated in the following situations:

1. Hypotension: Systolic blood pressure (SBP) < 90 mmHg or a drop of >30 mmHg below baseline.
2. Extreme Heart Rates: Severe bradycardia (heart rate < 50 bpm) or marked tachycardia (heart rate > 100 bpm in the absence of symptomatic heart failure).
3. Right Ventricular (RV) Infarction: Suspect RV infarction in patients with an inferior wall STEMI. These patients are highly dependent on adequate preload to maintain cardiac output. Administering a preload reducer like NTG can cause profound and potentially fatal hypotension. Always obtain a right-sided ECG if inferior STEMI is suspected before giving NTG.
4. Phosphodiesterase-5 (PDE5) Inhibitors: Recent use of PDE5 inhibitors for erectile dysfunction or pulmonary hypertension (e.g., sildenafil or vardenafil within 24 hours; tadalafil within 48 hours). The combination of NTG and a PDE5 inhibitor can lead to severe, refractory hypotension.

Morphine

Morphine sulfate is a potent opioid analgesic and venodilator. It can reduce pain and anxiety, thereby decreasing sympathetic tone and myocardial oxygen demand.

Cautious Use in ACS

While previously a standard therapy, the routine use of morphine in ACS is now approached with caution. Recent studies have raised concerns regarding its interaction with oral P2Y12 receptor inhibitors (such as clopidogrel, ticagrelor, and prasugrel).

• Interaction: Morphine can delay the absorption and onset of action of these crucial antiplatelet agents, potentially reducing their efficacy during the acute phase of myocardial infarction.
• Current Recommendation: Morphine is indicated for patients with severe ischemic chest pain that is unrelieved by initial therapies, specifically after a trial of sublingual nitroglycerin (if not contraindicated). It is no longer considered a first-line agent for all ACS patients.
• Dosing: Typically administered intravenously in small increments (e.g., 2-4 mg IV initially, followed by 2-8 mg every 5-15 minutes as needed), carefully monitoring for respiratory depression and hypotension.

In summary, the initial pharmacological approach to ACS prioritizes immediate antiplatelet therapy with aspirin and targeted ischemia relief with nitroglycerin, while reserving oxygen for hypoxic patients and morphine for refractory pain, always mindful of critical contraindications.